Page 6 - Sun Pharma

Sun Pharma starts succession plan; Ganorkar succeeds Shanghvi as MD

Dilip Shanghvi to remain executive chairman while Ganorkar takes charge as MD from September 1 and Aalok Shanghvi is given additional charge of North America business

Sun Pharma appoints Kirti Ganorkar as MD after shareholders' approval

Gonarkar has been heading Sun Pharma's India business since 2019 and has previously held roles in marketing, new product introduction, among others, within the company

Sun Pharma halts development of SCD-044 drug after trial disappointment

Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis

Sun Pharma lines up $100 mn to commercialise niche products in FY26

Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million. Elaborating

Sun Pharma to invest $25 million in Pharmazz Inc; raises stake to 22.7%

The company noted that the initial $10 million tranche, along with $7.5 million from the second SAFE tranche, will be invested by or before May 31, 2025

Weak guidance, higher costs to weigh on Sun Pharma's FY26 outlook

Sun Pharma's FY26 revenue guidance disappoints Street expectations as higher specialty product costs in the US prompt brokerages to cut earnings estimates

Sun Pharma share price slips 5% after Q4 results; check key numbers here

Sun Pharma share price dropped after the company posted a mixed bag of results in the March quarter of financial year 2025 (Q4FY25).

Sun Pharma results: Profit down 19% at Rs 2,149.8 cr, revenue up 8%

Sun Pharma's Q4 net profit fell 19% to Rs 2,149.8 crore due to input costs and US sales dip while FY25 profit rose 14% with strong domestic growth and specialty push

Sun Pharma Q4 results: Net profit falls 19% to ₹2,153.9 cr, revenue up 8%

Sun Pharma posted a 19% drop in Q4 profit to ₹2,153.9 crore, while revenue rose 8.5%. India formulation sales grew 13.6%, and a ₹5.5 final dividend has been recommended

Q4 results today: ITC, Sun Pharma, GMR Airports on May 22; see full list

Q4 FY25 company results today: Emcure Pharmaceuticals, Honasa Consumers, and Reliance Home Finance will be among 164 companies to post earnings reports for the January-March quarter on May 22

Pharma shares in focus; GSK, Jubilant, Eris, Gland, Torrent rally up to 8%

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as investors responded positively to strong Q4 results and favourable FY26 outlook

Sun Pharma Q4 preview: Analysts expect 18% jump in profit; check details

Sun Pharma Q4 results date: Sun Pharma is scheduled to announce its fourth quarter results on Thursday, May 22, 2025

Sun Pharma gets USFDA approval for new device to treat skin disease

The company says that the new device is more compact and easier to use than its predecessor

Nifty Pharma drops 2% after Trump reveals plans to lower US drug cost

The US President has predicted that pharmaceutical prices could drop 30 per cent to 80 per cent in America

Stock downfall: The side effects are real, but Sun Pharma stays on its feet

Growth hormone kicks in as India's largest pharma firm's vital signs hold amid generic strain

Sun Pharma stock up 2.15% as US court clears alopecia drug launch

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 million in FY27

Pharma stocks surge as Trump puts 90-day hold on planned tariffs

Nifty Pharma has fallen by 12.8 per cent so far this year, with Natco Pharma and Granules India leading the plunge

Here's why Sun Pharma share price advanced 5% in trade on April 11; details

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of Leqselvi (deuruxolitinib).

US court clears Sun Pharma to launch Leqselvi for alopecia areata treatment

Sun Pharma is now preparing to launch the drug in US markets after facing legal issues since November 2024

5 pharma stocks that you should stay away from given their tech charts

Technical charts hint that pharma shares such as Cipla, Lupin, Sun Pharma, Zydus Lifesciences and Gland Pharma could slide up to 23% as Trump tariff threat on pharma import looms.